BIRZEIT PHARMACEUTICALS COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.08 USD | -0.49% |
|
-2.39% | -6.64% |
| 25/02 | Birzeit Pharmaceuticals Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 09/01 | What does the Gotham City report say about Grifols? | RE |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 97.67 | 101.3 | 102.6 | 109.5 | 171 | 169.4 |
| Enterprise Value (EV) 1 | 88.09 | 91.77 | 93.12 | 97.74 | 155.5 | 152.2 |
| P/E ratio | 12.4 x | 10.6 x | 13.9 x | 9.07 x | 21.5 x | 27.3 x |
| Yield | 2.92% | 4.13% | 2.78% | 1.77% | 2.27% | - |
| Capitalization / Revenue | 2.75 x | 2.93 x | 2.86 x | 2.41 x | 3.63 x | 3.93 x |
| EV / Revenue | 2.48 x | 2.65 x | 2.6 x | 2.15 x | 3.31 x | 3.53 x |
| EV / EBITDA | 9.56 x | 9.72 x | 10.9 x | 8.16 x | 13.9 x | 17.5 x |
| EV / FCF | 32.3 x | 35.9 x | 16.7 x | -83.7 x | -159 x | 29.2 x |
| FCF Yield | 3.1% | 2.79% | 6% | -1.19% | -0.63% | 3.42% |
| Price to Book | 1.32 x | 1.3 x | 1.3 x | 1.19 x | 1.67 x | 1.54 x |
| Nbr of stocks (in thousands) | 38,765 | 38,765 | 38,765 | 38,765 | 38,765 | 38,765 |
| Reference price 2 | 2.520 | 2.613 | 2.647 | 2.825 | 4.410 | 4.370 |
| Announcement Date | 31/03/19 | 05/04/20 | 18/04/21 | 31/03/22 | 29/03/23 | 15/04/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 35.55 | 34.58 | 35.85 | 45.47 | 47.03 | 43.13 |
| EBITDA 1 | 9.212 | 9.437 | 8.568 | 11.98 | 11.22 | 8.676 |
| EBIT 1 | 7.641 | 7.828 | 6.882 | 10.31 | 9.559 | 7.18 |
| Operating Margin | 21.5% | 22.64% | 19.19% | 22.68% | 20.32% | 16.65% |
| Earnings before Tax (EBT) 1 | 8.808 | 10.29 | 8.151 | 13.38 | 9.024 | 7 |
| Net income 1 | 7.904 | 9.525 | 7.369 | 12.08 | 7.947 | 6.116 |
| Net margin | 22.24% | 27.55% | 20.55% | 26.56% | 16.9% | 14.18% |
| EPS 2 | 0.2039 | 0.2457 | 0.1901 | 0.3116 | 0.2050 | 0.1600 |
| Free Cash Flow 1 | 2.727 | 2.556 | 5.585 | -1.167 | -0.979 | 5.212 |
| FCF margin | 7.67% | 7.39% | 15.58% | -2.57% | -2.08% | 12.09% |
| FCF Conversion (EBITDA) | 29.61% | 27.09% | 65.19% | - | - | 60.08% |
| FCF Conversion (Net income) | 34.51% | 26.84% | 75.79% | - | - | 85.23% |
| Dividend per Share 2 | 0.0735 | 0.1078 | 0.0735 | 0.0500 | 0.1000 | - |
| Announcement Date | 31/03/19 | 05/04/20 | 18/04/21 | 31/03/22 | 29/03/23 | 15/04/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 9.58 | 9.51 | 9.49 | 11.8 | 15.4 | 17.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 2.73 | 2.56 | 5.59 | -1.17 | -0.98 | 5.21 |
| ROE (net income / shareholders' equity) | 11.3% | 12.6% | 9.31% | 14.1% | 8.08% | 5.9% |
| ROA (Net income/ Total Assets) | 5.59% | 5.2% | 4.36% | 6.11% | 5.09% | 3.62% |
| Assets 1 | 141.3 | 183.3 | 168.9 | 197.7 | 156.3 | 169.1 |
| Book Value Per Share 2 | 1.900 | 2.010 | 2.030 | 2.370 | 2.650 | 2.840 |
| Cash Flow per Share 2 | 0.0500 | 0.1300 | 0.0700 | 0.0300 | 0.0800 | 0.0800 |
| Capex 1 | 2.83 | 4.22 | 0.5 | 0.93 | 3.59 | 3.33 |
| Capex / Sales | 7.95% | 12.2% | 1.4% | 2.04% | 7.63% | 7.73% |
| Announcement Date | 31/03/19 | 05/04/20 | 18/04/21 | 31/03/22 | 29/03/23 | 15/04/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.64% | 158M | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- BPC Stock
- Financials Birzeit Pharmaceuticals Company